EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior

Giovanna Revilla iD, Nuseibah Al Qtaish iD, Pablo Caruana iD, Myriam Sainz-Ramos, Tania Lopez-Mendez, Francisco Rodriguez, Verónica Paez-Espinosa iD, Changda Li iD, Núria Fucui Vallverdú, Maria Edwards, Antonio Moral iD, José Ignacio Pérez und 7 weitere

Biomolecules · 2023

DOI: 10.3390/biom13111647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Giovanna Revilla und 18 weiteren Autor:innen. Beteiligte Einrichtung: Research Biomedical Institute (IIB) Sant Pau, C/Sant Quintí 77, 08041 Barcelona, Spain. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Nanoparticles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, Fondo Social Europeo (FSE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenvatinib, a tyrosine kinase inhibitor (TKI) approved for the treatment of progressive and radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), is associated with significant adverse effects that can be partially mitigated through the development of novel drug formulations. The utilization of nanoparticles presents a viable option, as it allows for targeted drug delivery, reducing certain side effects and enhancing the overall quality of life for patients. This study aimed to produce and assess, both in vitro and in vivo, the cytotoxicity, biodistribution, and therapeutic efficacy of lenvatinib-loaded PLGA nanoparticles (NPs), both with and without decoration using antibody conjugation (cetuximab), as a novel therapeutic approach for managing aggressive thyroid tumors.

Methods

Poly(lactic-co-glycolic acid) nanoparticles (NPs), decorated with or without anti-EGFR, were employed as a lenvatinib delivery system. These NPs were characterized for size distribution, surface morphology, surface charge, and drug encapsulation efficiency. Cytotoxicity was evaluated through MTT assays using two cellular models, one representing normal thyroid cells (Nthy-ori 3-1) and the other representing anaplastic thyroid cells (CAL-62). Additionally, an in vivo xenograft mouse model was established to investigate biodistribution and therapeutic efficacy following intragastric administration.

Results

The NPs demonstrated success in terms of particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, and cetuximab distribution across the surface. In vitro analysis revealed cytotoxicity in both cellular models with both formulations, but only the decorated NPs achieved an ID50 value in CAL-62 cells. Biodistribution analysis following intragastric administration in xenografted thyroid mice demonstrated good stability in terms of intestinal barrier function and tumor accumulation. Both formulations were generally well tolerated without inducing pathological effects in the examined organs. Importantly, both formulations increased tumor necrosis; however, decorated NPs exhibited enhanced parameters related to apoptotic/karyolytic forms, mitotic index, and vascularization compared with NPs without decoration.

Conclusions

These proof-of-concept findings suggest a promising strategy for administering TKIs in a more targeted and effective manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsNanoparticlesHumansAnimalsMicePolylactic Acid-Polyglycolic Acid CopolymerCetuximabLactic AcidPolyglycolic AcidGlycolsTissue DistributionIodine RadioisotopesQuality of LifeCell Line, TumorErbB ReceptorsDrug CarriersPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

EGFRlenvatinibnanoparticlesthyroid

Substanzen

Polylactic Acid-Polyglycolic Acid CopolymerCetuximabLactic AcidPolyglycolic AcidGlycolsIodine RadioisotopesErbB ReceptorsDrug CarrierslenvatinibPhenylurea Compounds

Autor:innen und Institutionen

  • Research Biomedical Institute (IIB) Sant Pau, C/Sant Quintí 77, 08041 Barcelona, Spain.
  • Departament of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, C/Antoni M. Claret 167, 08025 Barcelona, Spain.
  • Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), C/Monforte de Lemos 3-5, 28029 Madrid, Spain.
  • NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
  • Pharmacy Department, College of Pharmacy, Amman Arab University, P.O. Box 2234, Amman 11953, Jordan.

ORCID-Profile: Giovanna Revilla, Nuseibah Al Qtaish, Pablo Caruana, Verónica Paez-Espinosa, Changda Li, Antonio Moral, Juan Carlos Escolà-Gil, José Luis Pedraz, Idoia Gallego, Rosa Corcoy, María Virtudes Céspedes, Gustavo Puras

Förderung

  • Ministerio de Ciencia e Innovación
  • Instituto de Salud Carlos III
  • Fondo Social Europeo (FSE)
  • Spanish “Ministerio de Ciencia, Innovación y Universidades” and “Instituto de Salud Carlos III”
  • “Instituto Salud Carlos III, Madrid, Spain” (PFIS) and Fondo Social Europeo (FSE)
  • PFIS predoctoral contract
  • Miguel Servet II
  • European Social Fund (ESF Investing in Your Future), Spain

Zitieren

APA

Revilla, G., Al Qtaish, N., Caruana, P., Sainz-Ramos, M., Lopez-Mendez, T., Rodriguez, F., Paez-Espinosa, V., Li, C., Vallverdú, N. F., Edwards, M., Moral, A., Pérez, J. I., Escolà-Gil, J. C., Pedraz, J. L., Gallego, I., Corcoy, R., Céspedes, M. V., Puras, G., & Mato, E. (2023). Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior. Biomolecules. https://doi.org/10.3390/biom13111647

Vancouver

Revilla G, Al Qtaish N, Caruana P, Sainz-Ramos M, Lopez-Mendez T, Rodriguez F, et al. Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior. Biomolecules. 2023. doi:10.3390/biom13111647

BibTeX
@article{Revilla2023,
  author = {Revilla, Giovanna and Al Qtaish, Nuseibah and Caruana, Pablo and Sainz-Ramos, Myriam and Lopez-Mendez, Tania and Rodriguez, Francisco and Paez-Espinosa, Verónica and Li, Changda and Vallverdú, Núria Fucui and Edwards, Maria and Moral, Antonio and Pérez, José Ignacio and Escolà-Gil, Juan Carlos and Pedraz, José Luis and Gallego, Idoia and Corcoy, Rosa and Céspedes, María Virtudes and Puras, Gustavo and Mato, Eugènia},
  title = {Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13111647}
}
Kostenlos starten →